{"product_id":"ultragenyx-business-model-canvas","title":"Ultragenyx  Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx Business Model Canvas: Blueprint for Rare-Disease Commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Ultragenyx's business model—this concise Business Model Canvas maps value propositions, key partners, revenue streams, and growth levers to show how the company commercializes rare-disease therapies and scales long-term value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Commercial Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx maintains a long-term commercial alliance with Kyowa Kirin for Crysvita, sharing launch and marketing costs and tapping Kyowa Kirin’s global infrastructure; Crysvita net sales reached about $1.1bn in 2024, easing Ultragenyx’s commercialization burden. By end-2025, partnerships expanded with regional distributors in Asia and Latin America, covering over 30 additional markets to speed uptake and reduce country-specific capex.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx partners with smaller biotechs and academia to in-license rare-disease candidates—e.g., the 2020 collaboration with Mereo BioPharma on setrusumab—keeping a pipeline across gene therapy and mRNA; by end-2025 Ultragenyx reported 25+ programs and ~$1.2B in R\u0026amp;D spend (2024 FY) supporting these deals. These collaborations use milestone payments and tiered royalties to align incentives toward successful trials and approvals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and CDMO Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx maintains in-house manufacturing but contracts specialized CDMOs for modalities and scale; these partners supply technical expertise and GMP capacity to produce complex biologics and gene therapies under strict FDA\/EMA standards.\u003c\/p\u003e\n\u003cp\u003eBy Q4 2025, CDMO relationships were central to scaling recently approved gene therapies—company disclosures and filings cite multi‑site CDMO capacity expansions aimed to meet projected global demand of tens of thousands of doses and support revenue targets in the low hundreds of millions by 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUltragenyx partners with groups like EveryLife Foundation for Rare Diseases and disease-specific organizations to shape trial recruitment and regulatory strategy, using patient-journey insights to guide development; in 2024 Ultragenyx cited patient-group collaboration in 18+ trials and reported a 27% faster enrollment versus industry benchmarks.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18+ trials in 2024 involved patient-group support\u003c\/li\u003e\n\u003cli\u003e27% faster enrollment vs industry norms (2024)\u003c\/li\u003e\n\u003cli\u003eInsights used for IND\/ NDA strategy and endpoint selection\u003c\/li\u003e\n\u003cli\u003eEnsures product features match rare-disease patient needs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Provider and Institutional Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborations with specialized medical centers and academic hospitals enable Ultragenyx to run complex trials for ultra-rare diseases, accessing patient cohorts often numbering fewer than 100 and shortening enrollment by up to 30% versus broad-site models.\u003c\/p\u003e\n\u003cp\u003eThese sites provide primary data collection, help set diagnostic protocols, and have aided Ultragenyx in securing multiple regulatory designations—e.g., rare pediatric disease vouchers and 20+ orphan drug approvals through 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrimary trial sites for \u0026lt;100-patient cohorts\u003c\/li\u003e\n\u003cli\u003eEnrollment speed +30% vs broad sites\u003c\/li\u003e\n\u003cli\u003eContributed to 20+ orphan approvals (through 2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx: $1.1B Crysvita, 25+ pipeline partners, 30+ markets, 20+ orphan wins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx leverages Kyowa Kirin and 30+ regional distributors for Crysvita (net sales ~$1.1B in 2024), CDMOs for GMP gene-therapy scale, 25+ partnered pipeline programs, patient-group ties speeding enrollment ~27%, and academic sites contributing to 20+ orphan approvals through 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner Type\u003c\/th\u003e\n\u003cth\u003eKey Metric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial\u003c\/td\u003e\n\u003ctd\u003eCrysvita sales\u003c\/td\u003e\n\u003ctd\u003e$1.1B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003eMarkets added\u003c\/td\u003e\n\u003ctd\u003e30+ (by end‑2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline\u003c\/td\u003e\n\u003ctd\u003ePrograms\u003c\/td\u003e\n\u003ctd\u003e25+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eAnnual\u003c\/td\u003e\n\u003ctd\u003e$1.2B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient groups\u003c\/td\u003e\n\u003ctd\u003eFaster enrollment\u003c\/td\u003e\n\u003ctd\u003e+27% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003eOrphan approvals\u003c\/td\u003e\n\u003ctd\u003e20+ (through 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Ultragenyx outlining customer segments, channels, value propositions, key resources and partners, cost and revenue structures, and go-to-market strategies aligned with its rare-disease biopharma operations and investor-ready presentation needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Ultragenyx’s business model with editable cells, highlighting how rare-disease R\u0026amp;D, specialty partnerships, and orphan drug pricing relieve strategic and operational pain points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx advances discovery and clinical development across small molecules, enzyme replacement, and gene therapy, moving candidates from bench to dose-finding through rigorous preclinical work; R\u0026amp;D spend was about $660M in 2024 and was refocused to cut pipeline attrition by ~30% by end-2025. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Management and Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltragenyx runs global, multi-site trials for ultra-rare diseases, coordinating regulators in 30+ countries and the FDA\/EMA to meet complex CMC and endpoint demands; their 2024 pipeline included 8 late-stage programs requiring cross-jurisdictional harmonization.\u003c\/p\u003e\n\u003cp\u003eThey design trials for tiny cohorts (often \u0026lt;50 patients), using natural history studies as external controls to boost power; for example, their 2023 burosumab-like programs cited historical-control effect sizes to achieve statistical significance with 20–40 patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Navigation and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx holds ongoing talks with FDA, EMA, and other agencies to secure orphan designations and fast-track status, supporting 2025 pipeline filings; preparing NDAs\/BLAs (e.g., 2024 BLA submission for vosoritide successor) requires extensive clinical and CMC data to prove safety and efficacy.\u003c\/p\u003e\n\u003cp\u003eMaintaining global manufacturing and safety-reporting compliance consumes large resources—Ultragenyx reported R\u0026amp;D and SG\u0026amp;A of $1.08 billion in FY2024—driving continuous updates to quality systems and pharmacovigilance across jurisdictions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Manufacturing and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eUltragenyx runs advanced manufacturing at its Bedford, MA gene therapy site to produce high-quality AAV viral vectors and proteins, with 2025 yields improved to meet rising commercial and clinical demand.\u003c\/p\u003e\n\u003cp\u003eConsistency and purity are strict KPIs—batch deviation risks could harm patient safety and FDA\/EMA standing—so quality control and process validation are core operations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBedford AAV\/vector facility\u003c\/li\u003e\n\u003cli\u003e2025 yield increases support commercial scale\u003c\/li\u003e\n\u003cli\u003eQC focuses on purity, potency, safety\u003c\/li\u003e\n\u003cli\u003eRegulatory compliance (FDA\/EMA) critical\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Launch and Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eUltragenyx leads commercial launch and market access through physician education, payer negotiations, and logistics; in 2024 it reported $573M revenue, using outcomes data to secure coverage and pricing that support long-term access.\u003c\/p\u003e\n\u003cp\u003eA specialized rare-disease sales force targets ~1,200 expert clinicians globally, driving uptake while negotiating durable reimbursement terms with major US payers covering ~85% lives.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhysician education: targeted outreach to ~1,200 experts\u003c\/li\u003e\n\u003cli\u003ePayer value: $573M 2024 revenue shows access wins\u003c\/li\u003e\n\u003cli\u003eDistribution: hub models ensure specialty logistics\u003c\/li\u003e\n\u003cli\u003eReimbursement: negotiated coverage across ~85% US lives\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx ramps R\u0026amp;D and manufacturing—$660M spend, 8 late‑stage programs, 30% less attrition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx runs end-to-end rare-disease R\u0026amp;D, global multi-site trials, and GMP AAV\/protein manufacturing, spending ~$660M on R\u0026amp;D in 2024 and $1.08B R\u0026amp;D+SG\u0026amp;A; 2024 revenue was $573M while 2025 yield gains cut pipeline attrition ~30% and support 8 late-stage programs across 30+ countries.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$660M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D+SG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$1.08B (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$573M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLate-stage programs\u003c\/td\u003e\n\u003ctd\u003e8 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory reach\u003c\/td\u003e\n\u003ctd\u003e30+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline attrition cut\u003c\/td\u003e\n\u003ctd\u003e~30% by end-2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget clinicians\u003c\/td\u003e\n\u003ctd\u003e~1,200 global experts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Ultragenyx Business Model Canvas—not a mockup or sample—and reflects the exact file you will receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you’ll instantly get this same professional, ready-to-use document in its full form, formatted for easy editing and presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749032636793,"sku":"ultragenyx-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ultragenyx-business-model-canvas.png?v=1772212508","url":"https:\/\/matrixbcg.com\/products\/ultragenyx-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}